Cargando…
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute
This trial compared the efficacy and toxicity of standard first-line treatment with paclitaxel/carboplatin versus paclitaxel/carboplatin plus sorafenib in patients with advanced ovarian carcinoma. Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-12...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430260/ https://www.ncbi.nlm.nih.gov/pubmed/25556916 http://dx.doi.org/10.1002/cam4.376 |
_version_ | 1782371156566736896 |
---|---|
author | Hainsworth, John D Thompson, Dana S Bismayer, John A Gian, Victor G Merritt, William M Whorf, Robert C Finney, Lindsey H Dudley, B Stephens |
author_facet | Hainsworth, John D Thompson, Dana S Bismayer, John A Gian, Victor G Merritt, William M Whorf, Robert C Finney, Lindsey H Dudley, B Stephens |
author_sort | Hainsworth, John D |
collection | PubMed |
description | This trial compared the efficacy and toxicity of standard first-line treatment with paclitaxel/carboplatin versus paclitaxel/carboplatin plus sorafenib in patients with advanced ovarian carcinoma. Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-125 levels after maximal surgical cytoreduction were randomized (1:1) to receive treatment with paclitaxel (175 mg/m(2), 3 h infusion, day 1) and carboplatin (AUC 6.0, IV, day 1) with or without sorafenib 400 mg orally twice daily (PO BID). Patients were reevaluated for response after completing 6 weeks of treatment (two cycles); responding or stable patients received six cycles of paclitaxel/carboplatin. Patients receiving the sorafenib-containing regimen continued sorafenib (400 PO BID) for a total of 52 weeks. Eighty-five patients were randomized and received treatment.Efficacy was similar for patients receiving paclitaxel/carboplatin/sorafenib versus paclitaxel/carboplatin: overall response rates 69% versus 74%; median progression-free survival 15.4 versus 16.3 months; 2 year survival 76% versus 81%. The addition of sorafenib added substantially to the toxicity of the regimen; rash, hand–foot syndrome, mucositis, and hypertension were significantly more common in patients treated with sorafenib. The addition of sorafenib to standard paclitaxel/carboplatin did not improve efficacy and substantially increased toxicity in the first-line treatment of advanced epithelial ovarian cancer. Based on evidence from this study and other completed trials, sorafenib is unlikely to have a role in the treatment of ovarian cancer. |
format | Online Article Text |
id | pubmed-4430260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44302602015-05-18 Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute Hainsworth, John D Thompson, Dana S Bismayer, John A Gian, Victor G Merritt, William M Whorf, Robert C Finney, Lindsey H Dudley, B Stephens Cancer Med Cancer Research This trial compared the efficacy and toxicity of standard first-line treatment with paclitaxel/carboplatin versus paclitaxel/carboplatin plus sorafenib in patients with advanced ovarian carcinoma. Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-125 levels after maximal surgical cytoreduction were randomized (1:1) to receive treatment with paclitaxel (175 mg/m(2), 3 h infusion, day 1) and carboplatin (AUC 6.0, IV, day 1) with or without sorafenib 400 mg orally twice daily (PO BID). Patients were reevaluated for response after completing 6 weeks of treatment (two cycles); responding or stable patients received six cycles of paclitaxel/carboplatin. Patients receiving the sorafenib-containing regimen continued sorafenib (400 PO BID) for a total of 52 weeks. Eighty-five patients were randomized and received treatment.Efficacy was similar for patients receiving paclitaxel/carboplatin/sorafenib versus paclitaxel/carboplatin: overall response rates 69% versus 74%; median progression-free survival 15.4 versus 16.3 months; 2 year survival 76% versus 81%. The addition of sorafenib added substantially to the toxicity of the regimen; rash, hand–foot syndrome, mucositis, and hypertension were significantly more common in patients treated with sorafenib. The addition of sorafenib to standard paclitaxel/carboplatin did not improve efficacy and substantially increased toxicity in the first-line treatment of advanced epithelial ovarian cancer. Based on evidence from this study and other completed trials, sorafenib is unlikely to have a role in the treatment of ovarian cancer. BlackWell Publishing Ltd 2015-05 2014-12-31 /pmc/articles/PMC4430260/ /pubmed/25556916 http://dx.doi.org/10.1002/cam4.376 Text en © 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Research Hainsworth, John D Thompson, Dana S Bismayer, John A Gian, Victor G Merritt, William M Whorf, Robert C Finney, Lindsey H Dudley, B Stephens Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute |
title | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute |
title_full | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute |
title_fullStr | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute |
title_full_unstemmed | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute |
title_short | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute |
title_sort | paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage iii/iv epithelial ovarian cancer: a randomized phase ii study of the sarah cannon research institute |
topic | Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430260/ https://www.ncbi.nlm.nih.gov/pubmed/25556916 http://dx.doi.org/10.1002/cam4.376 |
work_keys_str_mv | AT hainsworthjohnd paclitaxelcarboplatinwithorwithoutsorafenibinthefirstlinetreatmentofpatientswithstageiiiivepithelialovariancancerarandomizedphaseiistudyofthesarahcannonresearchinstitute AT thompsondanas paclitaxelcarboplatinwithorwithoutsorafenibinthefirstlinetreatmentofpatientswithstageiiiivepithelialovariancancerarandomizedphaseiistudyofthesarahcannonresearchinstitute AT bismayerjohna paclitaxelcarboplatinwithorwithoutsorafenibinthefirstlinetreatmentofpatientswithstageiiiivepithelialovariancancerarandomizedphaseiistudyofthesarahcannonresearchinstitute AT gianvictorg paclitaxelcarboplatinwithorwithoutsorafenibinthefirstlinetreatmentofpatientswithstageiiiivepithelialovariancancerarandomizedphaseiistudyofthesarahcannonresearchinstitute AT merrittwilliamm paclitaxelcarboplatinwithorwithoutsorafenibinthefirstlinetreatmentofpatientswithstageiiiivepithelialovariancancerarandomizedphaseiistudyofthesarahcannonresearchinstitute AT whorfrobertc paclitaxelcarboplatinwithorwithoutsorafenibinthefirstlinetreatmentofpatientswithstageiiiivepithelialovariancancerarandomizedphaseiistudyofthesarahcannonresearchinstitute AT finneylindseyh paclitaxelcarboplatinwithorwithoutsorafenibinthefirstlinetreatmentofpatientswithstageiiiivepithelialovariancancerarandomizedphaseiistudyofthesarahcannonresearchinstitute AT dudleybstephens paclitaxelcarboplatinwithorwithoutsorafenibinthefirstlinetreatmentofpatientswithstageiiiivepithelialovariancancerarandomizedphaseiistudyofthesarahcannonresearchinstitute |